Powody, dla których warto zastosować metforminę o przedłużonym uwalnianiu (XR) Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2019
Słowa kluczowe:
metfomina o przedłużonym uwalnianiu XR, cukrzyca typu 2
##plugins.themes.bootstrap3.article.main##
Abstrakt
Cukrzyca jest chorobą przewlekłą wymagającą intensywnego leczenia już od chwili rozpoznania. Lekiem, po który sięga się najczęściej w cukrzycy typu 2, jest metformina. Na rynku dostępne są preparaty metforminy o natychmiastowym (IR, immediate release), powolnym (SR, slow release) i przedłużonym (XR, extended release) uwalnianiu. W niniejszej pracy przedstawiono powody, dla których warto stosować preparat metforminy o przedłużonym uwalnianiu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Szymborska-Kajanek, A., Wróbel, M., Rokicka, D., & Strojek, K. (2019). Powody, dla których warto zastosować metforminę o przedłużonym uwalnianiu (XR) . Medycyna Faktów , 12(1(42), 64-68. https://doi.org/10.24292/01.MF.0119.11
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
2. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2019. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Kliniczna 2019; 8(1).
3. Davies M.J., D’Alessio D.A., Fradkin J. et al.: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669-2701.
4. Collier C.A., Bruce C.R., Smith A.C. et al.: Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2006; 291(1): E182-E189.
5. Bailey C.J., Turner R.C.: Metformin. N. Engl. J. Med. 1996; 334(9): 574-579.
6. Chen H.S.: Old age may not be a contraindication to the use of metformin. J. Chin. Med. Assoc. 2010; 73(12): 615-616.
7. Schlender L., Martinez Y.V., Adeniji C.B.M.C. et al.: Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. Geriatr. 2017; 17(supl. 1): 227.
8. Timmins P., Donahue S., Meeker J. et al.: Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin. Pharmacokinet. 2005; 44(7): 721-729.
9. Bhansali A., Masoodi S.R.: Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus. J. Assoc. Physicians India 2005; 53: 441-445.
10. Asche C., LaFleur J., Conner C.: A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes. Clin. Ther. 2011; 33(1): 74-109.
11. Dailey G., Kim S.M., Lian J.F.: Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin. Ther. 2001; 23(8): 1311-1320.
12. Aggarwal N., Singla A., Mathieu C. et al.: Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes. J. Tradit. Complement. Med. 2018; 8(4): 506-514.
13. Fujioka K., Pans M., Joyal S.: Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin. Ther. 2003; 25(2): 515-529.
14. Scarpello J.H.: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br. J. Diabetes Vasc. Dis. 2001; 1: 28-36.
15. Schwartz S., Fonesca V., Berner B. et al.: Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006; 29(4): 759-764.
16. Levy J., Cobas R.A., Gomes M.B.: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol. Metab. Syndr. 2010; 2: 16.
17. Donnelly L.A., Morris A.D., Pearson E.R.: Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes. Metab. 2009; 11(4): 338-342.
18. Blonde L., Dailey G.E., Jabbour S.A. et al.: Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr. Med. Res. Opin. 2004; 20(4): 565-572.
19. Sweeny M., DeFronzo R., Scinta W.: Tolerability of metformin gastroretentive formulation (M-GR) in patients previously intolerant of metformin [ADA abstract 729-P]. Diabetes 2010; 59(supl. 1): A199.
20. Jabbour S., Ziring B.: Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad. Med. 2011; 123(1): 15-23.
21. Fujioka K., Brazg R.L., Raz I. et al.: Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes. Metab. 2005; 7(1): 28-39.
22. Derosa G., D’Angelo A., Romano D. et al.: Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. Drug Des. Devel. Ther. 2017; 11: 1481-1488.
23. Holman R.R., Paul S.K., Betel A. et al.: 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N. Engl. J. Med. 2008; 359: 113.
2. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2019. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Kliniczna 2019; 8(1).
3. Davies M.J., D’Alessio D.A., Fradkin J. et al.: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669-2701.
4. Collier C.A., Bruce C.R., Smith A.C. et al.: Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2006; 291(1): E182-E189.
5. Bailey C.J., Turner R.C.: Metformin. N. Engl. J. Med. 1996; 334(9): 574-579.
6. Chen H.S.: Old age may not be a contraindication to the use of metformin. J. Chin. Med. Assoc. 2010; 73(12): 615-616.
7. Schlender L., Martinez Y.V., Adeniji C.B.M.C. et al.: Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. Geriatr. 2017; 17(supl. 1): 227.
8. Timmins P., Donahue S., Meeker J. et al.: Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin. Pharmacokinet. 2005; 44(7): 721-729.
9. Bhansali A., Masoodi S.R.: Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus. J. Assoc. Physicians India 2005; 53: 441-445.
10. Asche C., LaFleur J., Conner C.: A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes. Clin. Ther. 2011; 33(1): 74-109.
11. Dailey G., Kim S.M., Lian J.F.: Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin. Ther. 2001; 23(8): 1311-1320.
12. Aggarwal N., Singla A., Mathieu C. et al.: Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes. J. Tradit. Complement. Med. 2018; 8(4): 506-514.
13. Fujioka K., Pans M., Joyal S.: Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin. Ther. 2003; 25(2): 515-529.
14. Scarpello J.H.: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br. J. Diabetes Vasc. Dis. 2001; 1: 28-36.
15. Schwartz S., Fonesca V., Berner B. et al.: Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006; 29(4): 759-764.
16. Levy J., Cobas R.A., Gomes M.B.: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol. Metab. Syndr. 2010; 2: 16.
17. Donnelly L.A., Morris A.D., Pearson E.R.: Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes. Metab. 2009; 11(4): 338-342.
18. Blonde L., Dailey G.E., Jabbour S.A. et al.: Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr. Med. Res. Opin. 2004; 20(4): 565-572.
19. Sweeny M., DeFronzo R., Scinta W.: Tolerability of metformin gastroretentive formulation (M-GR) in patients previously intolerant of metformin [ADA abstract 729-P]. Diabetes 2010; 59(supl. 1): A199.
20. Jabbour S., Ziring B.: Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad. Med. 2011; 123(1): 15-23.
21. Fujioka K., Brazg R.L., Raz I. et al.: Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes. Metab. 2005; 7(1): 28-39.
22. Derosa G., D’Angelo A., Romano D. et al.: Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. Drug Des. Devel. Ther. 2017; 11: 1481-1488.
23. Holman R.R., Paul S.K., Betel A. et al.: 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N. Engl. J. Med. 2008; 359: 113.